Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
82 results
  • The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. [Journal Article]
    Expert Opin Drug Saf 2019; :1-6Navari RM
  • Introduction: Chemotherapy-induced nausea and vomiting is a significant clinical issue that affects patients' quality of life as well as treatment decisions. Significant improvements in the control of chemotherapy-induced nausea and vomiting have occurred in the past 15 years with the introduction of new antiemetic agents 5-HT3, receptor antagonists, neurokinin-1 receptor antagonists, and olanzap…
  • Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting. [Journal Article]
    Clin Pharmacol Drug Dev 2019; 8(7):850-860Wang X, Wang J, … Kansra V
  • Population pharmacokinetics of rolapitant and its active metabolite M19 were studied in 482 patients receiving this neurokinin-1 receptor antagonist in combination with a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV). Patients received a single dose of rolapitant (range, 9-180 mg) before administration of moderately o…
  • Rolapitant Is a Reversible Inhibitor of CYP2D6. [Journal Article]
    Drug Metab Dispos 2019; 47(6):567-573Glass SM, Leddy SM, … Furge LL
  • Rolapitant [(Varubi), 5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one] is a high-affinity NK1 receptor antagonist that was approved in September 2015 as a treatment for nausea and vomiting caused by chemotherapy. In vivo rolapitant moderately inhibits CYP2D6 for at least 7 days after one 180 mg dose. Due to the long inhibition time, we inve…
  • An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant. [Journal Article]
    Clin Pharmacol Drug Dev 2019; 8(2):152-159Zhang ZY, Wang J, … Wang X
  • Rolapitant, a selective and long-acting neurokinin-1 receptor antagonist, is approved in an oral formulation for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This pivotal open-label, randomized, single-dose, multicenter, parallel-group study assessed the bioequivalence of a single oral dose of 180 mg of rolapitant administered in tablet (2 × 90-mg tablets) or capsule …
  • Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects. [Journal Article]
    J Clin Pharmacol 2019; 59(4):488-499Wang X, Wang J, … Zhang ZY
  • Rolapitant (Varubi) is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced nausea and vomiting. Rolapitant is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. Unlike other neurokinin-1 receptor antagonists, rolapitant is neither an inhibitor nor an inducer of CYP3A4 in vitro. The objective of this analysis was to examine the pharmacokinetics of …
  • Errata. [Journal Article]
    Int J Pharm Compd 2018 Nov-Dec; 22(6):527Allen LV
  • Ketamine 50-mg/mL Injection, IJPC Jul/Aug 2013 pg 331. "Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date" IJPC Jul/Aug 2014 pg 348-350. "Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture" IJPC May/Jun 2018 pg 237.
  • Infusion reactions following administration of intravenous rolapitant at an academic medical center. [Journal Article]
    J Oncol Pharm Pract 2019; 25(7):1776-1783Cass AS, Odinet JS, … Crona DJ
  • In 2017, due to a fluid shortage secondary to Hurricane Maria's devastation of Puerto Rico, hospitals and health-systems began to substitute rolapitant for fosaprepitant as part of chemotherapy-induced nausea and vomiting prevention and treatment strategies. However, despite advantageous pharmacologic and formulation (e.g. long half-life, quicker time to onset, and lack of first-pass hepatic meta…
New Search Next